Hepatitis C virus (HCY) is the major cause of transfusion-associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Most, if not all, infections become persistent and about 60% of cases develop chronic liver disease with various outcomes ranging from an asymptomatic carrier state to chronic active hepatitis and liver cirrhosis, which is strongly associated with the development of hepatocellular carcinoma. Since the initial cloning of the viral genome in 1989, our knowledge of the molecular biology of HCY has increased rapidly and led to the identification of several potential targets for antiviral intervention. In contrast, the low replication of the virus in cell culture, the lack of convenient animal models and the high genome variability present major challenges for drug development. This review will describe candidate drug targets and summarize 'classical' and 'novel' approaches currently being pursued to develop efficient HCYspecific therapies.
Introduction
After the implementation of serological tests to diagnose infections by hepatitis A virus and hepatitis B virus (HBV), an additional parenterally transmitted agent was recognized in 1974 as the major cause of transfusion-associated hepatitis (for reviews see Cuthbert, 1994; Houghton, 1996) . Although the causative agent, previously referred to as non-A, non-B hepatitis (NANBH) virus could be transmitted experimentally to chimpanzees, the apparently low titres in infectious sera made its identification by conventional virological and immunological methods impossible. Only with the advent of recombinant DNA technology could the disease-causing agent, now termed hepatitis C virus (HCV), be cloned from a cDNA library by a 'blind' immunoscreening approach . Diagnostic tests to detect anti-HCV antibodies, developed soon thereafter, proved that HCV represented the predominant cause of transfusion-associated NANBH .
HCV infection is found throughout the world (Mast & Alter, 1993; Cuthbert, 1994; Houghton, 1996) . Prevalences among volunteer blood donors range from 0.4% (USA, UK) and 2% (Japan, Taiwan) to more than 14% (Egypt). The main route of transmission is parenteral and many HCV-infected individuals are intravenous drug users or recipients of blood or blood products. With the introduction ofblood donor screening to identify HCV carriers, the frequency of post-transfusion hepatitis has been reduced markedly. Despite this fact the prevalence is still high because 40% to 50% ofHCV cases are not associated with known risk factors like intravenous drug use, blood transfusion, needle-stick accidents, tattooing or, less frequently, sexual and congenital transmission. However, approximately two-thirds of these so-called 'sporadic' infections are in individuals with a low socio-economic background, which is often associated with some other type ofhigh risk behaviour, such as contact with a sexual partner or house-hold member who has used intravenous drugs.
Infections by HCV usually become chronic and lead to various clinical outcomes: an inapparent carrier state with normal liver function and no apparent sequelae, acute hepatitis and in about 50% of cases a chronic hepatitis (Cuthbert, 1994; McDonnell & Lucey, 1995; Houghton, 1996) . About 20% of chronic cases develop liver cirrhosis, which leads to liver failure in approximately 25% of individuals. Furthermore, chronic HCV infections, particularly those that lead to cirrhosis, are associated with a high risk of hepatocellular carcinoma; HCV is the second most common aetiological agent in the development of this disease Saito et al., 1990; Tanaka et al., 1991; Gerber, 1993; Shimotohno, 1993) .
The only treatment currently available for chronic HCV infection is interferon (IFN)-a. However, in only about 40% of treated patients do serum alanine aminotransferase (ALT, an indicator of liver damage) levels decrease to normal and after cessation of therapy about 70% of these responders relapse (Davis et al., 1989; Marcellin et al., 1991) . Overall, only about 25% of patients show long-term normalization of serum ALT levels. Although the benefical effects of INF-a appear to be enhanced in combination therapy with the purine nucleoside analogue ribavirin (Di Bisceglie et al., 1992; Kakumu et al, 1993; Reichard et al, 1993; Koskinas et al., 1995) preliminary data indicate that only about 40% of treated patients show a sustained response , demonstrating the urgent need for the development of more effective antiviral drugs.
This review will briefly summarize our current knowledge about the molecular biology of HCV, focusing on potential targets for antiviral therapy. It will describe classical and novel approaches currently being undertaken to combat effectively this insidious agent. 
Nature of the infectious agent
Owing to the low virus titres in infectious sera and the failure to generate virus-like particles with recombinant expression systems, the molecular composition of HCV virions has not been studied extensively. HCV particles isolated from pooled human plasma or detected in cell cultures were shown by electron microscopy to have a diameter of about 50-60 nm (Kaito et al., 1994; Shimizu et al., 1996a) . Determination of the buoyant density ofvirus particles showed that the majority of infectivity is found in fractions of 1.03-1.1 g mL-l (Bradley et al, 1991; Carrick et al, 1992; Hijikata et al., 1993a) . In addition, particles with lower and higher densities are also detected, corresponding to complexes with cellular lipoproteins and immunoglobulins, respectively (Miyamoto et al, 1992; Hijikata et al., 1993a; Thomssen et al, 1992 Thomssen et al, , 1993 Choo et al, 1995) .
Current evidence suggests that E1 and E2 are the major glycoproteins embedded into the lipid envelope (Matsuura et al, 1992; Ralston et al., 1993; Spaete et al., 1992; Dubuisson et al, 1994; Kaito et al, 1994) . Underneath the envelope is the nucleocapsid, presumably composed of multiple copies of the C protein (Matsumoto et al, 1996) . Within the nucleocapsid is the plus-strand RNA genome which has a length of about 9600 nucleotides (Fig. 1 into mature virus proteins. The ORF is flanked by 5' and 3' untranslated regions (UTRs) of about 340 and 230 nucleotides in length, respectively, which are important for translation of the viral polyprotein and RNA replication (see below). Recombinant expression systems have been used to identify HCV polyprotein cleavageproducts and to delineate their arrangement within the genome. As shown in Fig. 1 , the order of these proteins is (from the N to the C terminus): NH 2-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH (Hijikata etal., 1991a,b; Grakoui et al., 1993a; Selby et al., 1993; Tomei et al., 1993; Lin et al., 1994a , Mizushima et al, 1994a . For most of these proteins, distinct functions have been ascribed (Table 1 ). The C protein is a basic RNA-binding protein, believed to interact with the virus RNA to form the nucleocapsid (Santolini et al, 1994; Matsumoto et al, 1996) . E1 and E2 are heavily glycosylated transmembrane envelope proteins that form stable heterodimers (Ralston et al., 1993; Dubuisson et al., 1994; Selby et al., 1994) . These structural proteins are separated from the non-structural (NS) proteins by a short hydrophobic peptide (p7), the function of which for the virus life-cycle is unknown. As deduced from analogy to the closely related pestiviruses, p7 of HCV would not be a constituent of the virion (Elbers et al., 1996) . NS2, NS3, NS4A, NS4B, NS5A and NS5B are non-structural proteins involved in polyprotein processing and virus replication. NS2 and the N-terminal domain of NS3 form the NS2-3 proteinase (Grakoui et al., 1993b; Hijikata et al., 1993c; Hirowatari et al., 1993) .The N-terminal NS3 domain also constitutes a serine-type proteinase (Bartenschlager et al., 1993; Eckart et al., 1993; Grakoui et al., 1993c; Hirowatari et al., 1993; Tomei et al., 1993; Hijikata et al., 1993c; Manabe et al., 1994) , while the C-terminal domain ofNS3 has a nucleoside triphosphatase (NTPase)/ RNA helicase activity (Suzich et al, 1993; Kim et al, 1995; Gwack et al., 1996; Tai et al., 1996) . NS4A is a peptide cofactor, modulating the activity of the NS3 proteinase (Bartenschlager et al., 1994; Failla et al., 1994; Lin et al., 1994b; Tanji et al., 1995a) . The functions of NS4B and NS5A are still unclear. Interestingly, NS5A is modified by intensive phosphorylation and this modification is influenced by NS4A (Kaneko et al., 1994; Tanji et al., 1995b; Asabe et al., 1997) . NS5B has been shown to be an RNAdependent RNA polymerase (RdRp; Behrens et al., 1996) .
A similar genome organization is found in flaviviruses and, most notably, in pestiviruses ( Fig. 1 ; for reviews see Meyers & Thiel, 1996) . Despite a low overall sequence homology, the similarities of the hydrophobicity profiles of the viral polyproteins, the existence of short collinear regions of sequence homologies within the polyproteins, corresponding in part to proteins with analogous functions and activities, and the substantial sequence identity between the 5' UTRs of HCV and pesti-viruses indicate that HCV is a distant relative of the animal-pathogenic pestiviruses like bovine viral diarrhoea virus (BVDV) and, to a lesser extent, the flaviviruses like yellow fever virus (YFV; Miller & Purcell, 1990; Choo et al., 1991) . Consequently, HCV is now classified as the separate genus 'hepatitis C-like viruses' together with the genera jfavivirus and pestivirus in the family Flaviviridae (Murphy et al., 1995) .
In the search for liver disease-causing viruses other than hepatitis A-E viruses, several members of a new group of viruses were cloned. The first two members, termed GB virus A (GBV-A) and GB virus B (GBV-B) were cloned 
Viruses shown as examples are YFV (flavivirus; Rice ef 01., 1985) and the NADL isolate of BVDV (pestivirus; Collett, 1992 ; for nomenclature of viral proteins see Meyers & Thiel, 1996) . 5' and 3' UTRs are shown as thin lines and the polyproteins as boxes. The borders between individual cleavage products are indicated by dotted lines. Npro, N-terminal proteinase. Note that for GBV-B the genome organization is hypothetical and deduced essentiallyby sequence comparisons with HCV genotypes (Muerhoff ef a/., 1995) . 
Virus release
Wavy lines represent virus plus-or minus-strand RNA (thick and thin lines, respectively). The viral polyprotein is drawn as a bar with vertical lines representing proteolytic cleavage sites. The . large solid rectangle represents the host cell, the smaller rectangle drawn with a dotted line indicates the membrane-associated replication complex. possible targets for antiviral intervention at different stages of virus replication are indicated on the right. For details see text.
appearance of neutralization escape mutants Kato et al., 1993; Taniguchi et al., 1993) . Even within a patient HCV is found as a 'swarm' of mierovariants (quasispecies; Martell et al., 1992; Gretch et al., 1996) and it is this plasticity of the virus genome which will have several important consequences for the development of vaccines and effective therapeutics. First, preliminary data indicate that the course and severity of disease may depend on the infecting genotype and genotype Ib in particular appears to be associated with more severe pathogenesis (Pozzato et al., 1991; McOmish et al., 1993; Dusheiko et al., 1994; De Mitri et al., 1995) . Second, there is growing evidence that HCV strains vary in their responsiveness to IFN-a therapy, with type 1 viruses being more resistant than types 2 and 3 (Pozzato et al., 1991; Yoshioka et al., 1992; Chemello et al, 1994) . Third, sequence heterogeneity will make the development of vaccines more complicated because antigens from multiple genotypes probably have to be included. Fourth, it is likely that under selective pressure viruses resistant to specific antiviral therapeutics will emerge.
from the serum of tamarins (Sanguinus sp.) inoculated with serum from a human hepatitis patient with initials GB (Muerhoff et al., 1995) . Of these, only GBV-B appears to be exogenous to tamarins and causes a hepatic illness. Using degenerate PCR primers the same group cloned a related virus termed GBV-C from the sera of two African patients Leary et al., 1996) . In an independent approach another group cloned a virus tentatively termed hepatitis G virus (HGV; Linnen et al., 1996) from the sera of two patients from the US. However, sequence analyses demonstrated that GBV-C and HGV are virtually identical and thus they are distinct isolates of the same virus. All these viruses have a genomic organization closely resembling the flaviviruses and therefore can be regarded as novel members of the family Flaviviridae. Sequence similarities and the absence of a genomic sequence that encodes a nucleocapsid or core-like protein reveal that GBV-A and GBV-C/HGV are more closely related to each other than to GBV-B. The latter is most closely related to HCV not only in terms of genome organization ( Fig. 1 ) but probably also in terms of functions of the viral proteins (such as the viral proteinases), making GBV-B a potentially attractive surrogate animal model for HCY. Full-length or near full-length genome sequences of numerous HCV isolates have been reported (Chen et al., 1992; Okamoto et al., 1994; . Comparisons between these sequences revealed considerable genetic divergence and it is now well-established that several HCV genotypes are distributed throughout the world (Bukh et al., 1993) . Based on phylogenetic analyses, HCV isolates can be separated into types 1 through 6 containing subtypes a, b or c . HCV types 1,2 and 3 are widely distributed around the world with type la (the US prototype isolate) and type Ib (the Japanese prototype isolate) accounting for about 60% of global infections. In particular, type Ib has been identified in nearly all countries studied (Bukh et al., 1993; McOmish et al., 1994) . Type 4 is predominant in the Middle East and types 5 and 6 appear to be largely restricted to South Africa and Hong Kong, respectively (Bukh et al., 1993; Simmonds et al., 1993; McOmish et al., 1994) .
Sequence heterogeneity is distributed unevenly across the genome. As expected for cis-acting RNA sequences, the 5' UTR and part of the 3' UTR are highly conserved even between the most. distantly related genotypes, whereas sequences encoding the E proteins, particularly the hypervariable region at the N terminus of E2, are the most variable (Table 1; Hijikata et al., 1991b; Higashi et al., 1993) . These proteins are most likely required for virus attachment to the host cell and antibodies against them may contribute to virus neutralization, thereby imposing strong selective pressure for the
• The HCV replication cycle: a largely hypothetical model
Owing to the lack of convenient in vitro systems, studies examining HCV replication have been largely restricted to human patients or experimentally infected chimpanzees. In both cases viraemia generally occurs within 1 week after infection and can last for several months (Alter et aI., 1989) . Elevation in ALT as a result of release from damaged hepatocytes commences within 5 to 10 weeks postinfection. In the case of chronic infections, ALT levels typically fluctuate and individuals remain generally viraemic (Farci et al., 1991) , whereas in the remainder ALT levels return to normal with still detectable viraemia.
Hepatocytes appear to be a major site ofHCV replication. In addition, there is growing evidence that HCV can also replicate within mononuclear cells. Furthermore, preliminary data suggest the existence of latently HCVinfected peripheral blood mononuclear cells and that replication can be activated by certain stimuli (Zignego et aI., 1992) . Thus, a lymphotropism ofHCV could be relevant to the establishment of chronic infection and explain the frequently observed reinfection of transplanted liver grafts (Lumbreras et aI., 1994; Martell et aI., 1994) .
Studies on HCV replication so far have been hampered mainly by the lack of a tissue culture system to allowefficient virus propagation and the lack of an infectious cDNA clone. Thus, our current understanding of the molecular mechanisms of HCV replication is based essentially on characterizations of recombinant proteins and analogies to other plus-strand RNA viruses. On the basis of this limited information, the following hypothetical model can be proposed (Fig. 2) . Mter binding to a target cell, which may involve interactions between one or both E proteins and a cellular receptor, HCV penetrates the cell and the RNA genome is liberated from the nucleocapsid into the cytoplasm of the cell. Although still controversial, several reports have demonstrated that this RNA is translated by a cap-independent mechanism with the 5' UTR acting as an internal ribosome entry site (IRES; Yoo et al., 1992; Tsukiyama-Kohara et aI., 1992; Wang et al., 1993; Honda et al., 1996) . The resulting polyprotein is cleaved co-and post-translationally by cellular and. two viral proteinases into mature viral proteins. Translation occurs at the rough endoplasmic reticulum (rER) and viral proteins remain tightly associated with intracellular membranes probably forming a membrane-associated replication complex containing, among other viral and presumably also cellular proteins, the viral NS3 helicase and the NS5B RdRp. Within this complex the plus-stranded RNA genome is used as a template for synthesis of minus-strand RNA, for which the 3' UTR of the plus strand most likely is essential. The newly generated minus-strand RNAs serve as a template for the synthesis of new plus strands which in Antiviral Chemistry & Chemotherapy 8(4) Hepatitis C virus chemotherapy targets turn can be used for any of three purposes: (i) as a template for the synthesis of new minus strands; (ii) for translation of the polyprotein; and (iii) for incorporation into the nucleocapsid assembled from multiple copies of the C protein. The fact that the E proteins remain in the ER membrane and are not transported beyond the cis':Golgi Ralston et aI., 1993; Dubuisson et aI., 1994) suggests that viral nucleocapsids acquire their envelope by budding into the lumen of intracellular vesicles. In this case HCV virions might be exported via the host secretory pathway and virus release would not depend on cell lysis. Consistent with this notion, complex N-linked glycans were found on partially purified extracellular HCV particles (Sato et al., 1993) , suggesting virus transit through the Golgi.
In principle each of these steps in the virus life-cycle presents a potential target for antiviral intervention. However, most of them are largely hypothetical or poorly understood and for only some of these steps have we begun to understand the underlying mechanisms and components involved. From this point of view, potential targets for the development of antiviral therapeutics are: the viral proteinases, the NS3 helicase, the NS5B RdRp and the 5' and 3' UTRs (Fig. 2 ). The following sections will summarize our current knowledge about these targets and describe current approaches towards the development of classical and novel strategies of antiviral chemotherapy.
Virus proteinases
Cell-free transcription/translation and transient expression assays of RNAs derived from HCV cDNA clones have been used to characterize processing of the polyprotein. As deduced from sequences preceding the cleavage sites and the dependence on microsomal membranes in cell-free translation, processing of the structural-NS2 region appears to be mediated by host signal peptidases cleaving at the C-El, EI-E2, E2-p7 and p7-NS2 junctions ( Fig. 3 ; Hijikata et aI., 1991a; Grakoui et al., 1993c; Lin et aI., 1994a; Mizushima et aI., 1994a,b) . Some of these cleavages are not co-translational because processing intermediates, most notably an E2-p7-NS2 protein, can be detected in transfected cells (Lin et aI., 1994a; Mizushima et aI., 1994a; Lohmann et al., 1996) . Furthermore, as predicted by the signalase-mediated processing at the C-El site, the primary C-specific cleavage product appears to contain the El signal sequence, which may be removed by an additional signalase-mediated cleavage approximately 10 residues N-terminal of the primary site (Santolini et al., 1994; Hussy et al., 1996) . Processing of the non-structural proteins is mediated by two overlapping viral proteinases (Fig. 3) , the NS2-3 proteinase, cleaving at the NS2-3 junction most likely by Processing of the non-structural proteins mediated by the NS2-3 and the NS3 proteinase (solid arrows). Cleavage mechanisms, kinetics of processing and cofactors required by these proteinases are given. Positions given for the different cleavage sites refer to the amino acid position of the P1 residue within the complete polyprotein of HCY genotype 1b (Kato et 0/., 1990) .
an intramolecular reaction (Grakoui et al., 1993b; Hijikata et al., 1993c) and the NS3 serine-type proteinase, required for processing at the NS3-4A, NS4A-B, NS4B-5A and NS5A-B boundaries (Bartenschlager et al., 1993; Grakoui et al., 1993c; Hijikata et al., 1993c; Tomei et al., 1993) . So far, neither proteinase appears to be required for processing of the structural proteins.
Since cleavage of the structural proteins is mediated exclusively by cellular proteinases, development of inhibitors of these events is difficult to achieve. In contrast, the virus-encoded proteinases have several properties which are clearly distinct from related cellular enzymes, making these virus proteins attractive targets for antiviral intervention.
The NS2-3 proteinase
The first viral proteinase identified was the serine-type proteinase located in the N terminus ofNS3. Mutational inactivation of this enzyme completely blocks processing at all sites C-terminal ofNS3 but does not affect cleavage at the NS2-NS3 junction, suggesting that processing at this site is mediated by cellular signal peptidases or a second viral proteinase (Bartenschlager et al., 1993; Grakoui et al., 1993a; Tomei et al., 1993) . However, for several reasons processing by host signalases can be ruled out: (i) numerous charged residues are found upstream from the 286 NS2-NS3 junction (Grakoui et al., 1993b; Hirowatari et al., 1993) ; (ii) processing of in vitro-translated NS2-NS3 proteins does not require microsomal membranes, although at least for some HCV isolates examined they appear to enhance cleavage efficiency (Bartenschlager et al., 1993; Santolini et al., 1995) ; (iii) NS2-3 proteins expressed in Escherichia coliare cleaved at the authentic site (Komoda et al., 1994a) .
Deletion studies used to identify the minimum domain required for cleavage at the NS2-3 site mapped the Nand C-terminal boundaries between residues 898-923 and 1186-1207, respectively (Grakoui et al., 1993b; Hijikata et al, 1993c; Santolini et al., 1995) . Within this sequence no strong similarities to enzyme motifs typical of the trypsin, aspartate or papain superfamilies or the metalloproteinase families are found. As revealed by site-directed mutagenesis, His-952 and Cys-993 within the NS2 domain are essential for cleavage at the NS2-3 site (Grakoui et al., 1993b; Hijikata et al., 1993c) . Substitution of these residues by Ala completely blocks processing between NS2 and NS3 but does not affect cleavage at the NS3-dependent sites,while mutations inactivating the serine proteinase activity of NS3 have no effect on processing at the NS2-3 junction. Thus, although both proteinases overlap, their activities.can be separated genetically. The question of whether both proteinases influence each other • seems to depend on the particular HCV isolate examined or the expression system used. While in most cases studied inactivation of the NS2-3 proteinase does not affect processing at the NS3-dependent sites, one report describes a requirement for the proteolytic removal ofNS2 residues from the N terminus ofNS3 for efficient cleavage at all downstream sites (D'Souza et al., 1994) .
Sequences around the scissile bond of the NS2-3 site are highly conserved even between the most evolutionarily distant genotypes. A consensus sequence would read (from the P5 to the P6' position): G W/L RlK/S LLJ-APITAY [according to Berger & Schechter (1970) , the newly generated C terminus, after cleavage of the peptide bond, is designated P1 and is preceded by the P2 residue; the newly generated N terminus is designated P1' and is followed by P2' and so on]. In spite of this high conservation, cleavage at this site is remarkably resistant to single amino acid substitutions and only mutations thought to alter the conformation of the protein have dramatic effects (Hirowatari et al., 1993; Reed et al., 1995) . Otherwise the P1 and P1' positions, which contain amino acids that form the scissile bond, are the most sensitve to mutation. Replacement of the Pl Leu by Ala, Arg or Phe is tolerated, but replacement by Glu or Pro is not. Similarly, substitution of Val or Arg for the P1' Ala has little effect on cleavage, while substitution of Asp or Pro at this position dramatically inhibits cleavage. This preference at the P1 and P1' positions of the NS2-3 site resembles the preference described for neutral metalloproteinases like thermolysin, which shows specificity for hydrophobic amino acids at the P1' position. In agreement with the assumption that NS2-3 might be a metalloproteinase, Hijikata et al. (1993c) found a stimulatory effect of zinc ions on cleavage at the NS2-3 junction and an inhibitory effect of EDTA. However, whether zinc ions participate in the cleavage reaction or play a structural role remains to be determined. In this context it should be noted that zinc ions are important for proper folding of the NS3 serine proteinase domain Kim et al., 1996; Love et al., 1996) suggesting that proper conformation of the NS3 domain is a prerequisite for full activity of both proteinases.
At least two explanations can be given as to why the Nterminal NS3 domain is required for cleavage at the NS2-3 junction by the NS2-3 proteinase: (i) the enzymic activity resides in the NS2 domain and the NS3 domain is required for proper folding of the proteinase or the NS2-3 cleavage site; (ii) both domains are required to constitute the enzymically active proteinase. In this case the NS2-3 site is present within the enzyme which would be inactivated after cleavage. A similar mechanism of suicidal proteinase inactivation has been described for the chymotrypsin domain located in the C-terminal region of the Sindbis virus nucleocapsid protein. In this case, the serine proteinase activity required to liberate the capsid protein Antiviral Chemistry & Chemotherapy 8(4) Hepatitis C virus chemotherapy targets from the precursor cleaves at a site located within the substrate binding region of the proteinase itself (for a review see Strauss & Strauss, 1994) .
Development of therapy targeted against the NS2~3 proteinase would be greatly facilitated by an in vitro transcleavage assay utilizing purified recombinant proteinase and peptide substrates. However, as deduced from the absence of NS2-3 processing intermediates and the rapid cleavage kinetics observed in transfected cells or in vitro translations, processing at the NS2-3 site is most likely to be an autocatalytic (intramolecular) reaction. A first hint as to how to circumvent this problem and how to design a possible in vitro assay comes from studies showing that an NS2-3 proteinase carrying an inactivating mutation in the NS2 or NS3 sequence can be rescued by transcomplementation using an intact version of the defective region (Grakoui et al., 1993b; Reed etal., 1995) . For example, when a construct directing the expression of an NS2-3 proteinase, defective in the NS2 domain, is co-expressed with an intact NS2 region, processing is restored, although the level of cleavage is very low compared with the parental NS2-3 proteinase. Thus, bimolecular cleavage in principle is possible if the NS2-3 polypeptide to be cleaved contains either a functional NS2 region or the N-terminal NS3 domain and is complemented by a polypeptide which supplies the defective region. This result suggests that both molecules must contribute a functional subunit to allow formation of a proteinase which is capable of cleavage at the NS2-3 site. On one hand, this property will make the development of efficient in vitro test systems much more complicated, while on the other hand it demonstrates that the NS2-3 proteinase ofHCV is a highly specialized enzyme and it is this distinction from cellular proteinases which makes it an attractive target for antiviral therapy. However, given our lack of information concerning the structure of the NS2-3 proteinase, the details of the processing mechanism and the low cleavage efficiency obtained thus far in bimolecular reactions, further work is needed to set up better test systems which will allow high throughput screenings or the use of rational drug design.
The NS3-4A proteinase complex
The most intensively studied and therefore best understood target for antiviral therapy against HCV is the NS3 proteinase and efforts have culminated in the resolution of the X-ray crystal structure of this important enzyme Love et al., 1996) . Originally predicted on the basis of sequence comparisons between HCV and several other viral and cellular proteinases, the serine-type proteinase activity residing in the N-terminal NS3 domain has been proven experimentally by several' groups. Cellfree translation and transfection studies with HCV cDNAs have shown that this activity is essential for cleavage at all sites C-terminal of NS3 but dispensable for processing at all other known sites (Bartenschlager et al., 1993; Grakoui et al., 1993c; Hijikata et al., 1993c; Tomei et al., 1993) . The lack of detectable NS3-4A precursors, the inability to cleave the NS3-4A site in trans and the insensitivity of cleavage kinetics at this site to dilution strongly suggest that processing between NS3 and NS4A is an intramolecular (co-translational) reaction. In contrast, processing at the other NS3-dependent sites can be mediated in trans (Fig. 3; Bartenschlager Tomei et al., 1993; Lin et al., 1994b) .
Kinetic analyses revealed a preferential but not obligatory order of cleavages. As described above, processing between NS3 and NS4A is rapid and is followed by cleavage at the NS5A-B junction. The resulting NS4A-5A intermediate is processed more slowly, with cleavage at the NS4A-B site being preferred over processing at the NS4B-5A junction (Lin et al., 1994b; Bartenschlager et al., 1994; Tanji et al., 1994a; Failla et al., 1995) .
Studies aimed at the identification of factors required in addition to NS3 for efficient processing demonstrated that NS4A is a proteinase cofactor (Bartenschlager et al., 1994; Failla et al., 1994; Lin et al., 1994b; Tanji et al., 1995a) . While cleavages at the NS3-4A, NS4A-4B and NS4B-5A sites are absolutely dependent on NS4A, processing between NS5A and NS5B also occurs in its absence but for at least some genotypes efficiency is low and significantly enhanced by this cofactor. Proteinase activation can be mediated in trans (by NS4A expressed as a separate molecule) or in cis (by NS4A expressed as part of the substrate or as part of the proteinase).
The mechanism of how NS4A-mediated proteinase activation is achieved was and, to some extent, still is a mystery. A first hint came from co-precipitation studies demonstrating the formation of a detergent-stable NS3-4A complex (Hijikata et al., 1993b,c; Bartenschlager et al., 1995a; Failla etal., 1995; Satoh et al., 1995) . Deletion mapping identified the regions involved in this interaction. For the NS3 proteinase, it was shown that about 180 residues at the N terminus of NS3 are sufficient for proteolytic activity (Bartenschlager et al., 1994; Tanji et al., 1994b; Failla et al., 1995) . Removal of further residues from the NS3 C terminus completely destroys enzymatic activity whereas deletion of Nterminal residues leads to a gradual inactivation of the proteinase. While normal processing patterns are observed for NS3 proteinases lacking up to 14 N-terminal residues, deletion of 22 amino acids severely reduces cleavage at the NS4A-B site and completely blocks processing at the NS4B-5A site, but only moderately affects cleavage between NS5A and NS5B (Bartenschlager et al., 1994; Failla et al., 1995) . Furthermore, since this truncated proteinase no longer, or only very poorly, co-precipitates with NS4A, activation of NS3 is apparently achieved by the 288 interaction of NS4A with the proteinase, for which Nterminal NS3 sequences are essential (Bartenschlager et al., 1995b; Failla et al., 1995; Koch et al., 1996) . Interestingly, autocatalytic processing at the NS3-4A site is not affected even when 28 N-terminal residues are removed, although this proteinase can no longer interact with NS4A (Failla et al., 1995) . Possibly, processing at this cis site is affected primarily by polyprotein folding, helping to place NS4A in the appropriate position for NS3-mediated cleavage. Thus, an N-terminally truncated NS3-4A precursor may still undergo self-cleavage because the cofactor is covalently linked to the proteinase, thereby compensating a defective protein-protein surface. In summary, complex formation and proteinase activation require the N-terminal22 NS3 residues and it was shown that this region forms an autonomous NS4A-binding domain (Satoh et al., 1995) . Since the first 14 residues can be removed without dramatically reducing cleavage at the NS4A-dependent sites, this sequence appears to have an auxiliary function, most likely stabilizing the NS3-4A interaction (Bartenschlager et al., 1995b; Failla et al., 1995; Koch et al., 1996) .
NS4A is a 54 residue amphipathic peptide with a hydrophobic N terminus and a hydrophilic C terminus. Transient expression of constructs directing the expression ofN-and C-terminally truncated NS4A proteins mapped a minimum proteinase activation domain from Gly-21 to Ser-32 (Bartenschlager et al., 1995a,b; Tanji et al., 1995a) . This result was later confirmed with various in vitro trans-processing assays in which NS4A fragments were supplied as synthetic peptides and identified the central NS4A region as an autonomous proteinase activation domain (Butkiewicz et al., 1996; Shimizu et al., 1996b; Tomei et al., 1996) . Although most non-structural proteins, including NS4A, are tightly associated with intracellular membranes, at least in vitro membranes are not required for proteinase activation Koch et al., 1996; Tomei et al., 1996) .
From all these studies it is now well established that proteinase activation is mediated by complex formation for which N-terminal NS3 sequences and the central region of NS4A are essential. However, certain substitutions in the sequences involved in interaction or deletions, which have no effect on proteinase activation, reduce recovery of NS3-4A complexes suggesting that a weak overall association between both proteins is sufficient for activation (Bartenschlager et al., 1995b; . In this context, the tight association observed between authentic NS3 and NS4A proteins may have a different function. As shown by Tanji et al. (1995a) , NS4A is also required for association ofNS3 with intracellular membranes for which the N-terminal 20 NS4A residues, probably forming a transmembrane helix, are required. Given that the Cterminal NS3 domain is an NTPase/helicase (see below), membrane attachment of NS3 via NS4A, for which a more tight interaction might be required, would primarily be important for the formation of a membrane-associated replicase complex.
Various in vitro systems composed of NS4A-specific pep tides, recombinant purified NS3 proteinase from different sources and peptide substrates or substrates generated by in vitro translation or recombinant expression have been used to characterize the mechanism of NS4Amediated proteinase activation. The results can be summarized as follows: (i) Proteinase activation is mediated by formation of a 1:1 complex suggesting that the enzymically active proteinase is a heterodimeric NS3-4A protein complex (Steinktihler et al., 1996a,b) . (ii) Using P6-P4' decapeptides as substrates, the order of cleavage efficiency at the trans sites is the same as observed for authentic polyprotein precursors (NS5A-B>NS4A-B» NS4B-5A) demonstrating that primary structure around the scissile bond is an important determinant of processing efficiency (Steinktihler et al., 1996b) . (iii) NS4A increases cleavage rates at all sites but to very different extents. While cleavage efficiency (expressed as kc./K m ) is enhanced about threefold at the NS5A-B site, an ll-fold increase is found at the NS4A-B site and a 100-fold increase at the NS4B-5A site (Shimizu et al., 1996b; Steinktihler et al., 1996b) . (iv) Enhancement at the NS5A-B and the NS4A-B junctions is achieved essentially by an increase of k cat (three-and fivefold, respectively) whereas cleavage efficiency at the NS4B-5A site is enhanced by an increase of k cat and K m (16-and sixfold, respectively; Steinktihler et al., 1996b) . Thus, activation by NS4A is highest at the site which is cleaved most poorly by NS3 alone and activation is low at the site which is cleaved most efficiently by NS3 in the absence of cofactor.
(v) The NS4A-dependent increase of K m for NS4B-5A substrates indicates that at least in this case NS4A stabilizes the interaction between the proteinase and the substrate. In agreement with this assumption, a co-precipitation ofNS4A with an uncleaved NS4B-5B substrate has been described (Bartenschlager et a!., 1995b). (vi) Different physicochemical requirements (such as dependence on glycerol and detergents) for optimum proteinase activity were found for NS3 with or without NS4A suggesting a conformational rearrangement of the proteinase upon cofactor binding (Steinkuhler et a!., 1996b) . Overall, these results suggest that NS4A exerts its activation function by (i) induction of conformational changes in the NS3 proteinase creating an optimum environment for catalysis and (ii) at least in the case of the NS4B-5A site, by stabilization of the proteinase-substrate interaction.
Determination of N-terminal sequences of cleavage products generated by the NS3-4A proteinase complex allowed precise localization of the processing sites Antiviral Chemistry& Chemotherapy 8(4) Hepatitis C virus chemotherapy targets (Grakoui et a!., 1993c; Pizzi et al., 1994) . Sequence comparison of the residues flanking the scissile bonds identified a possible cleavage site recognition motif characterized by an acidic P6 residue, a Pl Cys at all trans sites or a Pl Thr at the 3-4A (cis) site and a residue with a small side chain at the Pl' position. A coni sensus sequence would therefore read: Asp/Glu-X~X-X-X Cys/Thr-l-Ser/Ala (where X is variable). Results from sitedirected mutagenesis (Kolykhalov et a!., 1994; Komoda et al., 1994b; Leinbach et al., 1994; Bartenschlager et a!., 1995a) , molecular modelling (Pizzi et al., 1994; and three-dimensional structure determination Love et a!., 1996) identified the Pl residue as the major determinant of substrate specificity and demonstrated that the Pl' position is highly tolerant to substitutions. Although the acidic residue at the P6 position is not required, for all deavage sites at least one additional acidic residue is found on the P side in close proximity to the scissile bond. As shown for the NS5A-B site, substitution of both acidic residues blocks cleavage, suggesting that an overall negative charge in the region just upstream of the scissile bond is important for efficient processing (Komoda et al., 1994b) .
For a given substitution, a site-dependent gradient in the inhibition was observed, with the NS3-4A site being least sensitive to mutagenesis, followed by the NS4A-B, NS4B-5A and NS5A-B junctions (Kolykhalov et al., 1994; Komoda et a!., 1994b; Leinbach et a!., 1994; Bartenschlager et a!., 1995a) . This result probably reflects the different mechanisms operating at the NS3-dependent sites. As described above, cleavage at the cis site seems to be governed primarily by polyprotein folding, compensating in part for less favourable Pl residues. In contrast, processing at the trans sites may be determined primarily by in teractions between the substrate binding pocket and the residues around the scissile bond. The NS5A-B site is the least influenced by the NS4A cofactor suggesting that the proteinase per se is relatively optimum for interaction with the substrate and thereby is most refractory to manipulations ofresidues around the NS5A-B scissile bond. In case of the other sites the proteinase-substrate interaction may be stabilized by interaction with NS4A such that mutations at the cleavage site are less deleterious.
Many of these biochemical studies have been substantiated and explained by the recent resolution of the threedimensional structure of the NS3 proteinase and the NS3-4A proteinase complex by X-ray crystallography Love et a!., 1996) . These studies revealed a number of important and particular features of this proteinase. First, in agreement with the observed inhibitor profile (Hahm et a!., 1995) , it has a chymotrypsin-like fold with structural similarities to the proteinase residing in the Sindbis virus capsid protein (Choi et a!., 1991). Second, the enzyme is composed of two domains. The central NS4A region (the activation domain) forms a j3-strand that intercalates into the N-terminal domain j3-sheet in the core of the enzyme. By forming such an intimate intermolecular j3-sheet with NS3, NS4A can be regarded as a true proteinase subunit. Third, a tetrahedrally-coordinated zinc ion complexed via three Cys residues and, through a water molecule, via one His-residue is present in the Cterminal domain. Given the distance from the active site of the enzyme, zinc appears to have a structural and not a catalytic role. Fourth, several loops involved in shaping the substrate binding channel in the case of structurally related chymotrypsin and elastase are missing, rendering the NS3 substrate binding groove rather featureless. The PI specificity pocket is shallow, non-polar and formed primarily by the side chains of invariant residues Phe-154, Ala-157 and Leu-135. As already predicted by Pizzi et al. (1994) , Phe-154 points into the pocket and the aromatic ring is likely to interact with the sulphhydryl group of PI Cys and, less favourably, with PI Thr. In agreement with this observation, substitution of Phe-154 and Ala-157 by smaller residues increases the size of the pocket, enabling the cleavageofsubstrates with a bulkier PI Phe 0 Koch & R Bartenschlager, unpublished results) .
During the last 3 years our knowledge about the structure and the properties of the NS3-4A proteinase complex has expanded rapidly and this will doubtless accelerate development of effective antiviral compounds. One important observation is the unusual substrate specificity, which is quite distinct from cellular serine-type proteinases suggesting that it should be possible to generate inhibitors with a high degree of selectivity for the virus enzyme. This assumption is further substantiated by the observation that classical inhibitors of serine proteinases in most cases are effective only at high concentrations (Hahm et al., 1995; Shoji et al., 1995) . Although formal proof that the NS3-4A proteinase is essential for the production of infectious virus is missing, it is very likely (i) because of its high conservation among all HCV isolates described so far and (ii) by analogy to the closely related flaviviruses (such as YFV), for which the importance of the analogous proteinase complex for virus replication has been proven (Chambers et al., 1990) .
At least two strategies for inhibition of the HCV enzyme can be envisaged. First, inhibition of the catalytic mechanism of the NS3 proteinase with compounds identified by high throughput screenings or rational drug design and second, construction of dominant NS3 or NS4A inhibitors. Given the availability of various in vitro assays (Bouffard et al., 1995; Kakiuchi et al., 1995; Overton et al., 1995; Suzuki et al., 1995; Butkiewicz etal, 1996; Shimizu et al., 1996b; Steinkuhler et al., 1996b) high throughput screenings are currently being performed and the first inhibitors have been identified . Using the same methodology, 290 efficacies of designed inhibitors can be evaluated quantitatively. With the availability of the three-dimensional structure of the NS3 proteinase as well as the NS3-4A proteinase complex, rational drug design, which has so far had to rely on structure modelling, should be facilitated. Concerning the second approach, several possibilities can be envisaged: (i) NS3 peptides acting as dominant negative inhibitors by competitively blocking the NS3 binding in NS4A; (ii) dominant negative NS4A peptides interacting with the substrate and blocking proteinase-substrate interaction; and (iii) engineered NS4A peptides or synthetic compounds acting as dominant negative inhibitors of the activation function of authentic NS4A. As a first step in this direction, Shimizu et al. (1996b) recently described an NS4A peptide in which Arg-28 was substituted by GIn and which inhibited proteinase activation in vitro by authentic NS4A. However, it should be kept in mind that in vivo, processing at the NS3-4A site, probably the first polyprotein cleavage event mediated by NS3, is a rapid (intramolecular) reaction and is most likely preceded by a co-translational interaction between NS3 and NS4A (Tomei et al., 1993; Bartenschlager et al., 1994; Lin et al., 1994b) . Given this rapid and efficient interaction, inhibition of complex formation may be difficult to achieve. Further studies will be required to evaluate whether peptides or small compounds can inhibit the NS3-4A interaction under these more stringent condition and thereby block maturation of the HCV polyprotein precursor within the infected cell.
Components of the viral replicase complex
Compared to the viral proteinases, in particular the NS3-4A complex, much less is known about the replicase complex and only very recently have two enzymic activities probably involved in RNA replication been identified: the NTPase/helicase activity residing in the C-terminal two-thirds of NS3 and the RdRp/terminal transferase (TNTase) activity residing in NS5B. Although it is not known whether these activities are indispensable for the virus life-cycle, analogies to related viruses strongly suggest that they are, identifying these enzymes as further attractive targets for development of antiviral therapies.
The NS3 helicase
Formation of ssRNA from RNA-RNA or DNA-RNA hybrids requires an RNA helicase activity. This enzyme is found in many RNA viruses and for poliovirus at least has been shown to be essential for the production of infectious virus progeny (Li & Baltimore, 1988) . All helicases intrinsically carry an RNA binding activity and an NTPase activity which hydrolyses nucleoside triphosphates to provide the energy source for unwinding. Sequence analysis of helicases has revealed several conserved amino acid sequence motifs, for which specific functions can be ascribed to only three so far: motifIA is probably involved in nucleoside triphosphate binding; motif II, characterized by the 'DEAD' sequence (in the case of all HCV isolates a 'DECH' sequence; Fig. 4a ), is possibly involved in nucleoside triphosphate binding and hydrolysis; and motif VI is part of a basic domain which might be involved in RNA binding (for reviews see Schimid & Linder, 1992; Fuller-Pace, 1994) . Corresponding motifs are found in the C-terminal two-thirds of HCV NS3 (Fig. 4a ) and the analogous proteins of flaviviruses and pestiviruses (Gorbalenya et al., 1989) . For recombinant NS3 proteins of HCV, BVDV and YFV, RNA-stimulated NTPase activities have been described (Wengler & Wengler, 1991; Suzich et al., 1993; Tamura et al., 1993; Warrener et al., 1993) and for HCV and BVDV these polypeptides were also shown to have RNA helicase activity Gwack et al., 1996; Hong et al., 1996; Tai et al., 1996; Warrener & Collett, 1995) . The characteristics of the HCV helicase can be summarized as follows: (i) The C-terminal 465 residues of NS3 are sufficient for NTPase and helicase activities Fig. 4a ).
(ii) The NTPase can hydrolyse all ribonucleotides and desoxyribonucleotides (Suzich et al., 1993) .
(iii) The NTPase activity is stimulated by polynucleotides, with poly(D) or poly(dD) achieving maximum stimulation (about sixfold; Suzich et al., 1993) . This stimulation is owing to increases in both k cat and K m values and requires divalent metal ions, preferably Mlf+.
(iv) HCV NS3 binds to homoribopolymers with the following order of affinities: poly(D)>>poly(A)>poly(C) or polyG (Gwack et al., 1996) .
(v) The RNA helicase unwinds RNA-RNA duplexes, RNA-DNA heteroduplexes and DNA-DNA duplexes without sequence specificity (Gwack et al., 1996; Tai et al., 1996) .
(vi) The directionality of the helicase is 3' to 5' with respect to the template strand (Hong et al., 1996; Tai et al., 1996) . Since the enzyme binds to substrates containing 5' or 3' single-stranded regions but not to blunt-ended substrates, the polarity of the RNA strand to which the helicase binds appears to be an important enzymatic determinant (Gwack et al., 1996; Tai et al., 1996) .
Overall, it is well established that NS3 ofHCV is an RNA helicase assumed to be essential for the virus life-cycle. Since this enzyme can be expressed in large quantities in an active form, the basis for the development of high throughput screenings is laid. As determined so far, the enzyme appears to harbour some unique properties which distinguish it from most cellular DNA and RNA helicases (for example DNA and RNA duplex unwinding with ATP as an energy source for both reactions; Tai et al., 1996) . However, many of its characteristics, including mode of action on natural (genomic) RNA, modulation of its activity by other proteins within the replicase complex and structure-function relationship are unknown. On the other hand, Subramanya et al. (1996) have solved the X-ray crystal structure of a DExx box DNA helicase. As deduced from comparison with distinct sequence motifs of other helicases and structure modelling they suggest that despite a low overall sequence homology most of the helicases, in particular those of the 3'-5' type, have a common structural fold. On the basis of this information structure modelling of the HCV NS3 helicase now seems possible, which should allow a rational drug design approach and accelerate the development of an effective inhibitor of this enzyme.
The NS5B RNA-dependent RNA polymerase
The second putative component of the viral replicase complex, the NS5B RdRp, is a membrane-associated phosphoprotein (Hwang et al., 1997 ) whose biochemical properties have been characterized recently, Using a purified NS5B protein expressed with recombinant baculoviruses in insect cells, Behrens et al. (1996) detected two different enzymic activities: an RdRp activity and a TNTase activity, both ofwhich acted on RNA without sequence specificity. The RdRp copies RNA templates and requires a primer, which at least under in vitro conditions is generated by a 'snap-back' mechanism (3'-terminal sequences fold back intramolecularly) leading to the formation of base-paired dimer-sized RNA molecules. This intramolecular priming is strongly preferred and exogenous DNA primers are used only when the 3'-OH end of the RNA molecule is chemically blocked (Behrens et al., 1996) . The RdRp displays a high processivity and can copy even full-length HCV genomes in vitro in the absence of any viral or cellular protein (V Lohmann, F Korner, U Herian and R Bartenschlager, unpublished results). Whether initiation of RNA synthesis in the infected cell is also mediated by intramolecular priming is not known but if it is, a specific ribonuclease would be required for cleavage of the RNA dimer.
While it is obvious that the RdRp is essential for viral replication (although formal proof is lacking) the significance of the NS5B-associated TNTase activity is less clear. Under in vitro conditions, the TNTase can add a ribonucleotide to the 3'-OH group of an RNA molecule in a template-independent manner. Although all four ribonuleotides are accepted, UTP is the preferred substrate followed by ATP, CTP and GTP (Behrens et al., 1996) . However, so far the possibility that this enzymic activity is exerted by a cellular protein co-purified with NS5B rather than by NS5B itself cannot be ruled out. Furthermore, it is not clear whether the TNTase activity is an in vitro artifact detectable only under conditions of limited ribonucleotide concentrations or whether it plays a role in viral RNA synthesis.
Sequence analysis of viral polymerases reveals four characteristic motifs present in a distinct linear arrangement and distinguished by one or two highly conserved amino acid residues in each motif (Poch et al., 1989) . These are an Asp in case of motif A, a Gly within motif B, the 'GDD 292 motif' (C) and a basic residue in motifD, which for nearly all viral enzymes is a Lys. For HCV, similar sequence motifs are found around the centre of NS5B (Fig. 4b) .
Using mutation analysis the importance of these sequences for RdRp activity could be demonstrated (V Lohmann, F Korner, U Herian and R Bartenschlager, unpublished results) . In most cases substitutions of the highly conserved residues (Asp-220, Gly-283, Asp-318 and Asp-319) drastically reduce or completely abolish polymerase activity, with motifs 'A:. and 'B' being most sensitive to alterations.
As deduced from the crystal structures of the Klenow fragment of E. coli (Yadav et al, 1994) , the T7 RNA polymerase (Sousa et al., 1993) and the human immunodeficiency virus (HIV) reverse transcriptase (Kohlstaedt et al., 1992; jacobo-Molino et al., 1993) , these four amino acid motifs cooperate to contribute to the formation of a wellordered domain designated the polymerase module. This module forms a hand-like domain important for the minimum polymerase function: template-directed nucleic acid polymerization. Functions distinct to each polymerase reside in domains N-and C-terminal of the polymerase domain and it seems likely that the same is valid for NS5B ofHCV.
Although we are far from a complete understanding of structure and function of this important enzyme, the first step towards development of RdRp inhibitors is complete. Comparable with the situation of the NS3 helicase, NS5B can be expressed in large quantities in enzymically active form and the purified protein doubtless will be used to develop in vitro assays to identify candidate inhibitors.
Cis-acting RNA sequences
During the last couple of years 'novel' approaches to antiviral therapy have emerged based on interference with functions of nucleic acids rather than proteins. For HCV and several other human pathogenic viruses, two strategies are being pursued: inhibition of virus replication by antisense oligonucleotides or by ribozymes. Both approaches have the advantage of high specificity but strictly depend on the presence of sequences highly conserved even between distantly related genotypes, predisposing the 5' and 3' UTR as potential targets. Since the real 3' end of the HCV genome was identified just 1 year ago (Tanaka et al., 1995 (Tanaka et al., , 1996 Kolykhalov et al., 1996; Yamada et al., 1996) , all efforts have so far focused on inhibition of the 5' UTR. This sequence is part of an IRES, whose 5' border was mapped to about nucleotide position 40 and which reaches about 30 nucleotides into the core ORF (nucleotide 370, with the authentic initiation codon for the polyprotein lying at nucleotide 342; Lu & Wimmer, 1996; Reynolds et al., 1995) . It is essential for efficient polyprotein translation and probably plays an important role in RNA replication and packaging as well. This sequence is highly structured by extensive base-pairing. In addition, an RNA pseudoknot structure is present upstream of the initiator AUG, indispensable for IRES function (Wang et al., 1995) .
To be effective, antisense oligodeoxynucleotides (ODNs) have to meet several criteria: (i) they must be stable in vivo; (ii) they must be able to enter and stay within the target cell; and (iii) they must be able to interact specifically with the viral sequence (for review see Stein & Cheng, 1993) . Concerning the first criterion, because of their resistance to nucleases in vitro and in vivo, phosphorothioate ODNs (S-ODNs) are currently the first choice. After hybridization to the target sequence, they exert their inhibitory effect both by direct interference with the function of the nucleic acid and by activation of cellular RNase H, cleaving the resulting DNA-RNA hybrid. With respect to the third criterion several groups have used structural information to devise S-ODNs targeted to the most highly conserved sequence in the HCV genome, the IRES. Using in vitro translation of subgenomic viral RNAs or reporter genes under the translational control of the HCV 5' UTR in rabbit reticulocyte lysates, ODNs targeted to sequences in close proximity of the initiator AUG were found to be most effective (Wakita & Wands, 1994; Alt et al., 1995; Mizutani et al., 1995; Vidalin et al., 1996) . Furthermore, two ODNs were identified that blocked translation from HCV IRES sequences of genotypes la, 1b and 2a, despite the presence of a nucleotide exchange in the targeted HCV sequence of the 2a isolate (Wakita & Wands, 1994; Vidalin et a, 1996) . To analyse any possible influence of chemical modification of the ODNs on inhibitory activity, Vidalin et al. (1996) compared ODNs with the natural structure, S-ODNs and ODNs with a-phosphodiester in which the anomeric configuration of the sugar moieties is inverted and which cannot induce cleavage by RNase H. They found that all ODNs effectively blocked HCV translation, but in case of S-ODNs this was due mainly to non-specific effects. Levels of inhibition obtained with natural ODNs and a-ODNs were comparable and involved both RNase H-dependent and RNase H-independent pathways.
Despite the potential of this experimental system to identify ODNs blocking translation of the HCV polyprotein (and presumably also virus replication), it is artificial and allows only a first screening because it does not account for the fact that (i) in the infected cell both plusstrand and minus-strand RNA are present and may form hybrids, which are not accessible for ODNs; (ii) the fulllength RNA may have an alternative structure in which target sites identified with subgenomic fragments are masked; and (iii) the viral RNA is probably complexed with cellular and viral proteins or packed into viral particles protecting them from ODNs. Thus, the results Antiviral Chemistry & Chemotherapy8 (4) Hepatitis C viruschemotherapy targets obtained with this experimental system have to be verified using infected cells or cells transfected with a replicationcompetent full-length HCV genome. As a first step in this direction, Hanecak et al. (1996) used a stable cell line expressing the 5' -terminal quarter of the HCV genome. From a panel of 50 S-ODNs they identified one targeted to a stem-loop structure within the 5' UTR known to be important for IRES function and one targeted to sequences spanning the AUG initiator of the polyprotein, both ofwhich reduced translation of core protein to about 20-30% of the untreated control. Furthermore, levels of HCV RNA were drastically reduced, most likely by the activation of RNase H. Although RNase H-mediated cleavage has the principle advantage of inhibition of protein translation and virus RNA replication, it might be limited by the fact that (i) RNase H -mediated degradation will reduce the concentration of bioavailable ODN; and (ii) HCV replicates in the cytoplasm of infected cells whereas the majority of ODNs and RNase H accumulates in the nucleus. From this point of view, 2' methoxyethoxy phosphodiester antisense oligonucleotides, which do not serve as substrate for RNase H, may be, in addition to a-ODNs, an alternative, Using this type of chemical modification, Hanecak et al. (1996) showed that an oligonucleotide, targeted to the sequence around the AUG initiation codon, efficiently inhibited core protein production without affecting the level ofHCV RNA in the cell. Thus, it is feasible to design antisense oligonucleotide inhibitors of translation that do not require RNase H activation.
The only indication that S-ODNs do indeed inhibit HCV replication in the infected cell comes from Mizutani et al. (1995) . Using an experimentally infected T cell line they showed that an 18-mer S-ODN complementary to sequences directly downstream of the initiation codon of the genomic 0 RF could block virus replication. When added directly into the cell culture medium at a final concentration of 10 !1M, plus-strand and minus-strand HCV RNA levels, as determined by strand-specific; RT-PCR, could be reduced to below the limit of detection. However, whether this is owing to a specific inhibition ofvirus replication or to other, non-specific effects is not kn~wn. Furthermore, since the level of replication in this system is very low and since quantification with PCR is difficult, data on the efficiency of inhibition in this cell culture system are not available.
Although for HCV we cannot foresee whether this approach will finally lead to an effective therapy, development of ODNs to inhibit gene expression of viruses has been described in several other cases including human T cell leukaemia virus type I (von Ruden & Gilboa, 1989), HIV (Matsukura et al., 1987 (Matsukura et al., , 1989 Agrawal et al., 1989) and HBV. In the latter case, in addition to in vitro studies (Goodarzi et al., 1990; Wu & Wu, 1992) two animal models were used to evaluate the efficiency of ODNs on virus gene expression and replication. First, using mice transgenic for the HBV X gene, Moriya et al. (1996) showed that an S-ODN targeted to the initiation codon of the transgene efficiently blocked its expression and prevented preneoplastic lesions in the liver of these animals. Second, treatment of Pekin ducks infected experimentally with duck HBV (a virus that is frequently used as an animal model for HBV), with an S-ODN targeted to the 5' region of the pre-S gene severely reduced virus gene expression and replication without detectable side effects (Offensperger et al., 1993) . Thus, in vivo inhibition of virus replication by S-ODNs is possible in principle.
Besides using antisense ODNs for the development of virus-specific chemotherapy, ribozymes present an alternative approach. For HCV, in an elegant study Lieber et al. (1996) presented data indicating that this approach is indeed feasible. Using PCR methodology, they cloned from a hammerhead ribozyme library six ribozymes acting on authentic HCV RNA isolated from infected liver tissue. Five ribozymes hybridized to sequences of the HCV plus-or minus-strand RNA in close proximity to the initiator AUG and one ribozyme hybridized to a sequence in the core region. When expressed with recombinant adenoviruses in CHO cells stably expressing the full-length genome of a HCV 1a isolate in plus or minus orientation, HCV RNA levels were reduced to beyond the level of detection by some of these ribozymes. Most notably, the authors established two HCV-infected hepatocyte cultures from HCV-infected transplant recipients with final-stage liver disease. One of these cultures was infected with HCV genotype 1a and the other with genotype Ib, the most prevalent types worldwide (see above). Upon infection with recombinant adenoviruses expressing any of the six ribozymes, HCV RNA levels were reduced to various extents. When cells were infected with a mixture of all six recombinant adenoviruses, HCV RNA became undetectable without affecting the mRNA level of a cellular gene used as a marker for cell toxicity. Inhibition was apparently dose-dependent because reduction ofHCV RNA levels was strongest in cells infected with recombinant viruses containing three copies of the ribozyme genes. Although many questions, including development of resistant HCV quasispecies and method of delivery, have to be evaluated before clinical trials can be considered, vector-mediated ribozyme therapy appears to be a strategy for the treatment ofHCV infection.
Conclusions and future directions
Since the original description of the causative agent of NANBH our knowledge about the molecular biology of HCV has increased rapidly. Several potential targets for 294 antiviral intervention have been identified and for most of them an in vitro assay is available which allows high volume 'random' screening of natural products, corporate databases of compounds, peptides, oligonucleotides and combinatorial chemical libraries. For the NS3-4A proteinase complex, the X-ray crystallographic structure was resolved and is expected to accelerate rational drug design. However, despite this progress several obstacles will have to be overcome before therapeutics become available. First, the high variation of the HCV genome demands compounds effective against all genotypes. Second, development of resistant viruses has to be considered as a major problem for treatment. However, as we have learned from clinical studies with HIV, this problem can be overcome at least to some extent by combination therapy. In this respect, development of compounds directed against different targets in HCV may be a prerequisite for successful therapy. Third, given the lack of a convenient tissue culture system to propagate HCV and the lack of an animal model other than the chimpanzee, the evaluation of antiviral compounds on inhibition of virus replication in infected cells is difficult. For this reason surrogate systems might be an important alternative. Besides two cell-based systems suitable for screening of NS3 proteinase inhibitors Song et al., 1996) several viral surrogate systems have been developed. For instance Lu & Wimmer (1996) described an HCV-poliovirus chimera in which the poliovirus IRES was replaced by the HCV IRES, yielding a viable chimeric virus which might be useful for testing of the inhibitory effects of ODNs on HCV IRES function. In an analogous approach, Hahm et al. (1996) constructed a chimeric poliovirus in which the NS3 proteinase was fused in frame to the N terminus of the poliovirus polyprotein. Viability of this virus requires proteolytic removal of NS3 and, hence, inhibition of NS3 reduces virus formation, allowing a rapid screening for intracellular proteinase inhibition. Similarly, an HCV-Sindbis virus chimera has been described whose replication and production of infectious progeny is dependent on the activity of the engineered NS3 proteinase (Filocamo et al., 1997) . While these systems depend on the replication of artificial engineered viruses, the recently cloned GBV-B virus, which in terms of polyprotein structure and processing appears to be most closely related to HCV (Muerhoff et al., 1995) might be an alternative. Since GBV-B efficiently replicates in tamarins (Sanguinus sp.) it might be used as a surrogate virus to test for proteinase inhibitors in an animal model. Transgenic animals expressing functional HCV proteins may provide another possibility to test for the inhibitory activity of an antiviral compound in an in vivo model. However, despite the potential of such surrogate systems to test intracellular inhibition of a target enzyme, they do not allow firm conclusions on the inhibition of HCV replication in the " infected cell. Since HCV seems to be designed by nature to replicate at low levels in infected cells, the development of cell culture systems which allow virus propagation at easily detectable titres will be a very difficult task. It remains to be seen whether antiviral compounds found to be effective in in vitro assays or surrogate systems will be testable in cell culture or animal models or whether they will go directly to clinical trials. In either case, given the progress made in the last couple of years, we can remain optimistic that effective antiviral therapeutics will become available. With an estimated 100 million chronic carriers worldwide, the need for effective antiviral therapy is obvious. Bartenschlager 
